Student or educator? Sign up with your school email and get 6 months of Pro free.
CoChat
Cited by 199

The DOI matches its Crossref record; 1 of the 1 references it cites were found in a registry or an index.

Clarithromycin-Resistant Genotypes and Eradication of Helicobacter pylori

De Francesco, Vincenzo, Margiotta, Marcella, Zullo, Angelo, Hassan, Cesare, Troiani, Laura, Burattini, Osvaldo, Stella, Francesca, Di Leo, Alfredo, Russo, Francesco, Marangi, Stefania, Monno, Rosa, Stoppino, Vincenzo, Morini, Sergio, Panella, Carmine, Ierardi, Enzo · 2006 · Annals of Internal Medicine

Abstract

BACKGROUND: Three point mutations (A2143G, A2142G, and A2142C) have been involved in Helicobacter pylori clarithromycin resistance. OBJECTIVE: To compare the eradication rates among the different point mutations and the efficacy of triple therapy and a sequential regimen according to genotypic resistance. DESIGN: Post hoc subgroup study from a multicenter, randomized trial. SETTING: Two hospitals in central and southern Italy between January and December 2001. PATIENTS: 156 patients with H. pylori infection. MEASUREMENTS: Real-time polymerase chain reaction for assessing clarithromycin resistance; histology, rapid urease test, and 13C-urea breath test at entry and after 4 to 6 weeks. INTERVENTION: 7-day triple therapy (20 mg of rabeprazole, 500 mg of clarithromycin, and 1 g of amoxicillin) in 75 patients or a 10-day sequential regimen (20 mg of rabeprazole plus 1 g of amoxicillin for 5 days and 20 mg of rabeprazole, 500 mg of clarithromycin, and 500 mg of tinidazole for the remaining 5 days) in 81 patients. All drugs were given twice daily. RESULTS: Helicobacter pylori infection was eradicated in 11 of 23 patients (48%) with the A2143G mutation and in 14 of 15 patients (93%) with either A2142G or A2142C strains (difference, 45 percentage points [95% CI, 15 to 65 percentage points]; P = 0.004). The sequential regimen achieved a higher cure rate than triple therapy in A2143G mutate strains (difference, 49 percentage points [CI, 8 to 72 percentage points]; P = 0.024). LIMITATIONS: The post hoc substudy design may require further confirmation. Other limitations are the accessibility to the tool and the cost of investigations (70 euros per patient). CONCLUSIONS: The A2143G mutation seemed to be associated with a very low eradication rate. The sequential regimen achieved a higher cure rate than standard therapy even in patients with these strains.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.7326/0003-4819-144-2-200601170-00006

Cites

1 of 1 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 1 references

Cited by

See all 199

Metadata

Authors
De Francesco, V., Margiotta, M., Zullo, A., Hassan, C., Troiani, L., Burattini, O., Stella, F., Di Leo, A., Russo, F., Marangi, S., Monno, R., Stoppino, V., Morini, S., Panella, C., & Ierardi, E.
Venue
Annals of Internal Medicine
Published
2006-01-17
Volume
144
Issue
2
Pages
94-100
ISSN
  • 0003-4819 (ISSN-L)
  • 1539-3704
OpenAlex
W2132339174
Cited by
199
References
1
FWCI
13.40
Type
journal article
Language
en
Open access
closed

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Clarithromycin-Resistant Genotypes and Eradication of Helicobacter pylori. https://app.cochat.ai/papers/10.7326/0003-4819-144-2-200601170-00006
The paper
De Francesco, V., Margiotta, M., Zullo, A., Hassan, C., Troiani, L., Burattini, O., Stella, F., Di Leo, A., Russo, F., Marangi, S., Monno, R., Stoppino, V., Morini, S., Panella, C., & Ierardi, E. (2006). Clarithromycin-Resistant Genotypes and Eradication of Helicobacter pylori. Annals of Internal Medicine. https://doi.org/10.7326/0003-4819-144-2-200601170-00006

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.